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CC BY-NC-ND license (http://creativeAbstract One of the simplest models for examining the interplay between bone formation
and resorption is the junction between the cranial bones. Although only roughly a quarter of
patients diagnosed with craniosynostosis have been linked to known genetic disturbances,
the molecular mechanisms elucidated from these studies have provided basic knowledge of
bone homeostasis. This work has translated to methods and advances in bone tissue engineer-
ing. In this review, we examine the current knowledge of cranial suture biology derived from
human craniosynostosis syndromes and discuss its application to regenerative medicine.
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Ideal model systems for studying biological processes
require three components: simplicity, controllability, andsion of Plastic and Recon-
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commons.org/licenses/by-nc-nd/physiologic relevance. In the investigation of bone homeo-
stasis, few models have been more useful than the cranial
suture. In terms of simplicity, there is no other model sys-
tem that exists for bone that can be isolated down to the
bare essentials for intramembranous ossification. Due to
the limited number of cell types and minimal changes in
mechanical forces that occur at cranial sutures, this system
allows for direct evaluation of the interactions between
osteoprogenitors, osteocytes, osteoclasts, the dura, and
the extracellular matrix. Mechanical load on the calvarium
is relatively limited considering that the skull is not a
weight bearing entity. Muscular pull on the bones is minimaland hosting by Elsevier B.V. This is an open access article under the
4.0/).
58 J.B. Maxhimer et al.in that there are only two muscles directly attached to the
cranial bones. In terms of control of the system, in vitro,
ex vivo, in vivo, investigation using multiple species, and
human syndromes with significant phenotypes can all be
used to systematically evaluate single molecular mecha-
nism. Finally, the significance of human phenotype based
on single gene mutations cannot be underscored enough.
The relevance of processes affecting osteogenesis in cranial
sutures is clearly not just an artificial laboratory entity but
an actual physiologic process with developmental conse-
quences. These revelations also inspired significant avenues
of investigation in bone tissue engineering. In this review,
we discuss several major pathways governing bone ho-
meostasis derived from craniosynostosis syndromes and
describe its translation to skeletal regeneration.
Cranial suture development and fusion
The mammalian cranial vault contains five bones: paired
frontal bones, paired parietal bones, and the occipital or
interparietal bone (Fig. 1). Four cranial sutures separate
the five bones: the sagittal suture exists between the two
paired parietal bones, the coronal suture between the
frontal and parietal bones, the metopic between the two
frontal bones, and the lambdoid between the occipital and
parietal bones. Malleability of the skull imparted by the
cranial sutures is essential for the birthing process and
subsequent growth of the brain. Growth of the calvarium is
typically perpendicular to the direction of the sutures as
the brain expands. In the event of a stenosed suture, the
compensatory growth occurs parallel to the stenosed suture
by expansion at the unaffected sutures. Ossification of the
skull occurs via intramembranous ossification from the
interplay between the suture mesenchyme and the dura.
With the exception of the metopic suture which closes
around 18 months of age, all other sutures close after
completion of cranial growth well into adulthood. Similar to
the human calvarium, the murine posterior frontal suture,
analogous to the metopic suture, is the only suture in the
mouse to fuse at about 40 days after birth.1,2Figure 1 Cranial bones and cranial sutures.Murine transgenic reporter gene models have now
demonstrated that development of the skull is derived
from a combination of neural crest and mesodermal line-
ages. Using two different transgenic mice that labeled cell
types with galactosidase under either the Wnt-1 or Mesp-1
promotors, Morriss-Kay and colleagues were able to
differentiate the origins of bony development of the skull
between the neural crest or mesodermal lineages.3,4 Their
landmark studies definitively demonstrated that the frontal
bone is neural crest in origin, the parietal bones are
mesodermal, and the occipital bone is a combination of the
two. During embryonic development, the coronal suture
contains a boundary between the neural crest derived
frontal bone on one side and the mesoderm-derived suture
mesenchyme and parietal bone on the other side.3,4 Simi-
larly, at the sagittal suture, there is also a boundary be-
tween neural crest and mesodermal lineages. This
boundary is likely important for the timing of suture
patency versus fusion.
Craniosynostosis, or early fusion of cranial sutures,
occurs in approximately 1 in 2000e2500 live births of
which the majority are nonsyndromic in nature.5,6 Single
suture nonsyndromic craniosynostosis accounts for over
80% of all craniosynostosis. Sagittal synostosis is the most
common form accounting for 40%e50% of all nonsyndromic
craniosynostosis with a prevalence of about 1.5 in 10,000
live births and a male to female ratio of 2.5:1. Unicoronal
craniosynostosis accounts for 0.7 in 10,000 live births with
a male to female ratio of 1:2.3.7 Metopic synostosis occurs
in 0.8 in 10,000 live births with a male to female ratio
of 3.3:1. Lastly, lambdoid synostosis occurs in about
0.7 in 10,000 live births with a male to female ratio of
2.2:1.
The consequences of early cranial suture fusion are both
visible and functional. With the exception of mild cases, the
majority of patients with craniosynostosis have character-
istic head shapes depending on the type of synostoses that
is present. This congenital anomaly is not only distressing to
parents, but it may also harbor functional consequences. In
multi-suture or syndromic cases, suture fusion has clearly
been related to increased intracranial pressure with po-
tential consequences in brain development.8,9 In non-
syndromic cases, several landmark studies have now
demonstrated that functional consequences also occur.
Persing and colleagues have recently published their pro-
spective, multi-center studies using a battery of neuropsy-
chiatric testing to show that total cranial vault remodeling
before 6 months of age improves outcomes. In addition,
their work also showed that minimally invasive endoscopic
strip craniectomies are definitively inferior to total cranial
vault remodeling even when completed at an early
age.10e12 Although these studies do not consider interme-
diate surgical techniques such as the pi procedure in cranial
vault reconstruction, their work is of great significance in
surgical decision making and states that a minimally inva-
sive correction for nonsyndromic sagittal synostosis
adversely affects the future intelligence and neuropsycho-
logical function of a child with craniosynostosis.
The etiology of craniosynostosis is varied. A number of
monogenetic alterations have been described, however,
factors such as advanced maternal age, advanced paternal
age, race, birth plurality, and gender have all been
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In terms of syndromic synostosis, more than 100 different
mutations have been described in relationship to cranio-
synostosis. In the Oxford cohort, 27% of 300 cases of cra-
niosynostosis have the following mutations: FGFR2 8.3%,
FGFR3 6.4%, Twist1 4.9%, EFNB1 1.8%, FAM20C < 1%,
LMX1B < 1%, structural chromosome anomalies 3.7%,
TCF12 w 1%, ERF 2.9%.14e16 In general, the genes contrib-
uting to craniosynostosis can be categorized to genes
encoding molecules that effect osteogenic upregulation,
osteoclastogenic downregulation, cell patterning, extra-
cellular matrix, apoptosis, cell proliferation, or vascular
function.13,16e18Table 1 Genes affected in major craniosynostosis
syndromes.
Craniosynostosis Gene Reference
Crouzon FGFR2, FGFR3, IL-11R 26e30
Apert FGFR2 31
Saethre-Chotzen Twist1, TCF12 14,32,33
Muenke FGFR3 17
Pfeiffer FGFR1, FGFR2 34,35
Boston-type Msx2 36
Beare-Stevenson FGFR2 37
Craniofrontonasal
dysplasia
EFNB1 38
Jackson-Weiss FGFR2 39Anatomic and cellular components of bone
homeostasis
Normal bone biology, like all biology, is a process that has
both positive and negative regulators. At the anatomic
level, bone formation and resorption occurs as part of two
major mechanisms of bone homeostasis: modeling and
remodeling. Bone modeling generates a net positive quan-
tity of bone at specific surfaces separate from the resorp-
tive surfaces. One physiologic example is provided by
Sarnat and colleagues who described that mandibular ramal
growth occurred at the posterior and inferior borders, while
resorption was prominent at the anterior border.19 In
contrast, bone remodeling couples osteoblast and osteo-
clast activity and is a process common in adult bone. This
coupling of bone formation and resorption is spatially
enclosed within specialized anatomic structures called
basic multicellular units (BMUs).20 The BMU is comprised of
osteoblasts, osteoclasts, and mature osteocytes within
mineralized bone matrix. Membrane bound and secreted
factors affecting both bone formation and resorption are in
a balance within the three major cell types. As we now
know from the craniosynostosis and pathologic bone dis-
eases, this balance can easily be dysregulated with pref-
erence towards either process.
At the cellular level, two major cell lineages are
responsible for bone homeostasis: osteoblasts and osteo-
clasts.21,22 Mesenchymal stem cells (MSCs) are pluripotent
cells that have the ability to differentiate into chon-
drocytes, adipocytes, osteoblasts, and myoblasts. The
osteoblastic lineage begins with the differentiation of MSCs
into a fibroblast colony forming unit (CFU-F), which is
further differentiated into pre-osteoblasts through the ac-
tion of a number of signaling pathways that are discussed
further below. Central to the signaling pathways is the
activation of Runx2, a master transcription factor in oste-
oblast differentiation. Osteoblasts are responsive to me-
chanical stimuli and growth factor receptor-mediated
signals.23 Following secretion of bone matrix, a population
of osteoblasts undergoes further differentiation to osteo-
cytes and remains embedded within the matrix. Osteo-
cytes, the most abundant cell type in bone, are
interconnected via dendritic processes and gap junctions to
each other, osteoblasts, and endosteal lining cells with
close proximity to osteoclasts. Although the exact purpose
of the osteocyte network is controversial, it likely has a role
as mechanical sensors for stress and injury.24,25 In addition,the discovery that osteocytes are the major source of
sclerostin, a Wnt antagonist, as well as RANKL suggest that
osteocytes may be the cell type holds the balance between
bone formation versus resorption.
Unlike the osteoblast lineage of cells, osteoclasts are
multinucleated cells differentiated from hematopoietic
stem cells (HSCs) that function to resorb and remodel
bone.21 Following differentiation of the HSC to monocyte
colony forming units (CFU-M), osteoclastogenesis is stimu-
lated by the action of macrophage colony stimulating factor
(M-CSF) and receptor activator of nuclear factor-kB (NF-kB)
(RANK). Osteoclasts exert their function by direct contact
with bone, resulting in the formation of resorption pits or
tunnels.Signaling bone formation
Multiple pathways have been identified to contribute to
osteogenesis. In cranial suture fusion, the most infamous
signaling pathway is the fibroblast growth factor receptor
(FGFR) family due to its frequent association to craniosy-
nostosis syndromes such as Crouzon, Apert, and Pfeiffer
syndromes (Table 1). For example, Apert syndrome is
caused by FGFR2 mutations and accounts for 40% of all
craniosynostosis syndromes.6 FGFR signaling is crucial to
both intramembranous and endochondral ossification and is
involved in proliferation, differentiation, and tissue heal-
ing.40 FGF receptors all contain an extracellular domain
with either 2 or 3 immunoglobulin like domains, a trans-
membrane domain, and a cytoplasmic tyrosine kinase
domain (Fig. 2). Most of the significant craniosynostosis
mutations occur in the extracellular domain resulting in a
dominant active effect. FGF receptors are expressed by
osteoprogenitor cells and FGF ligands are expressed by both
mesenchymal cells and osteoblasts. The FGFR family has
drawn the most attention as it has been shown to be
involved in the majority of syndromic cases of craniosy-
nostosis. A mutation in these genes ultimately results in a
gain of function which manifests in either enhanced ligand
affinity or less discrete binding.41,42
Within the FGFR signaling pathway, downstream medi-
ators have also been linked to craniosynostosis. Msx2 is part
of the highly conserved Msx homeobox gene family that
causes Boston type craniosynostosis.36,43 Msx2 expression is
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Figure 2 Members of the FGFR signaling pathway. FGFR receptors are characterized by two to three extracellular Ig-like domains
and two tyrosine kinase domains that mediate downstream signaling. The FGF ligand is typically bound to heparan sulfate in the
extracellular matrix in dimeric form. This allows potentially for binding of multiple FGFR. One of the negative regulators of FGFR
signaling is Twist, a basic helix-loop-helix transcription factor.
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genes in calvarial osteoprogenitor cells results in prolifer-
ation instead of differentiation of the cells.43,45 In the
mouse, Msx2 is expressed in the neural crest population
that gives rise to the calvarial bones and the dura. Runx2, a
major osteogenic effector, is also induced downstream of
the FGFR signaling pathway. Runx2 is essential for both
endochondral and intramembranous ossification.46 In cra-
niosynostosis, additional copies of Runx2 have been
detected in a small number of individuals causing pan-
synostosis and significant midface hypoplasia.47
Although a number of pathways essential to bone ho-
meostasis have not been directly associated with cranio-
synostosis, disruptions in FGFR signaling affect the
regulation of pathways such as the bone morphogenetic
protein (BMP) signals. BMPs, members of the transforming
growth factor-b (TGF-b) superfamily of growth factors, are
heterogeneous growth factors that have been shown to
promote osteogenesis, chondrogenesis, and organogenesis
via signaling through heteromeric BMP receptor (BMPR)
complexes.48 The BMPs are particularly significant in clin-
ical practice because two of its members (BMP-2 and -7) are
currently approved for use in therapeutic applications.49
BMPs are first synthesized as precursor proteins that
dimerize intracellularly. Upon dimerization, they are
cleaved at the consensus Arg-x-x-Arg site, yielding carboxy-
terminal mature dimers that are secreted (Fig. 3).
Following secretion, BMP dimers activate intracellular
processes by binding to BMPR complexes.50 Both type I and
type II BMPR are transmembrane serine threonine kinases.51
Type I BMPR are generally considered to be the high affinity
receptors that determine the specificity of BMP signaling
and type II receptors are the constitutively active receptors
that activate downstream processes after binding to type Ireceptors. However, this general rule has been challenged
by the binding patterns of certain BMPs such as BMP-9.52
The mode of BMPR oligomerization at the cell surface is a
determinant in downstream signaling pathways.53,54 In the
BMP-mediated signaling complex (also called the BMP-
induced signaling complex or BISC), BMP dimers bind to
type I BMPR dimers and recruit type II BMPR dimers to the
complex. This complex is internalized in caveolae and re-
sults in the activation of ERK, p38 MAPK, and PI3K pathways
without Smad activation. In contrast, type I and type II
BMPR can exist in a tetrameric preformed complex. When
BMP dimers bind to the tetrameric preformed complex, the
receptor Smads (Smad 1/5/8 or Smad 2/3) are recruited
and phosphorylated by the receptor. Internalization occurs
through a clathrin dependent endosomal route. Phosphor-
ylated receptor Smads associate with co-Smad (Smad 4) and
translocate to the nucleus to activate Smad-dependent
genes such as Id1-3. Crosstalk between the two pathways
occurs. Both ERK and p38 MAPK are activated by the Smad
independent pathway and both have the capabilities to
target receptor Smads for proteasomal degradation.55 Both
canonical and non-canonical pathways can induce osteo-
genic genes.
Inhibitors of BMP signaling such as Noggin are now known
to be important for suture patency.56 This is believed to
occur via a paracrine fashion from neural crest derived cells
in the dura. High FGF-2 activity in murine sutures has been
found to downregulate noggin expression at certain time
points which then permits endogenous BMP signaling and
subsequent fusion of the suture.57,58 Genetic disruptions of
the BMP pathway members have not been described in
human craniosynostosis, however, dysregulation of the
pathway is a byproduct of known craniosynostosis
mutations.
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Figure 3 Members of the BMPR signaling pathway. BMPR are heterotetrameric receptors. The type I receptor is a high affinity
receptor that directs specificity of BMP binding. The BMP ligand is secreted and binds its cognate receptor in dimeric form.
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FGFR pathway are also found in craniosynostosis syn-
dromes. Twist1, a basic helix-loop-helix transcription fac-
tor, is related to FGFR signaling in that it acts to direct
mesenchymal cell fate during skeletal development to-
wards both the chondrogenic and osteogenic lineages.
Twist1 has been found to have over 100 different mutations
and the majority of them causing a loss of function. The
mechanism of Twist1 directed lineage determination is
based on negative regulation of FGFR2 expression thereby
prolonging suture patency.59,60 The importance of Twist1 in
maintaining suture patency is further highlighted by a
recent description that, TCF12, the heterodimeric binding
partner for Twist1, is a cause for coronal synostosis.14
Heterozygous loss of function mutations resulting in hap-
loinsufficiency are associated with SaethreeChotzen syn-
drome for both Twist and TCF12. Twist is upstream of
the ephrins, which are membrane bound ligands for Eph
family receptor kinases known to regulate cell adhesion
and migration during development. Specifically, the
Twist-Ephrin axis has been demonstrated in murine models
to be essential to the neural crest-mesoderm boundary in
the developing cranial suture.61 Missense mutations of
EFNB-1 are the most commonly found abnormalities
contributing to the development of craniofrontonasal
dysplasia (also called craniofrontonasal syndrome) and
other craniosynostoses.38,62
While osteoblast activity has been at the forefront of
much of these studies, there still exists a fine balance be-
tween the cellular interaction of osteoblasts and osteo-
clasts which is at the core of bone biology and
development. All of these studies have led to a better un-
derstanding of cranial suture genetics and biology, but little
light has been shed upon the role of the osteoclast and its
activity in suture patency.Balancing bone formation to bone resorption
A controlled amount of resorption in bone regeneration and
remodeling is part of normal bone physiology. However, the
balance of formation versus resorption is precarious and can
be tipped in favor of the former or the latter depending on
the local microenvironment. In pathological circumstances
such as chronic inflammation or bony metastases in cancer,
the ratio of osteoclastogenic factors to osteoclast inhibitors
increases and a net resorption of bone occurs.63,64 Osteoclast
differentiation is supported by mesenchymal cells through
cell-to-cell contact and paracrine effects which are regu-
lated by both macrophage colony-stimulating factor (M-CSF)
and the receptor activator of NF-kB (RANK), RANK ligand
(RANKL), and osteoprotegerin (OPG) axis (Fig. 4).65e67 Unlike
osteoprogenitors, osteoclasts derive from hematopoietic
progenitors. However, a number of different cell types are
necessary to direct monocyte to osteoclast differentiation
by supplying RANKL. These cell types include osteoblasts,
osteocytes, stromal cells, B and T cells, synovial fibroblasts,
hypertrophic chondrocytes, and other osteoclasts. Analo-
gous to lymphocytes, the mechanism for differentiation and
activation is a two-signal process requiring both M-CSF and
RANK receptors. Although both cytokines are essential for
osteoclastogenesis, M-CSF is primarily involved in stimu-
lating the survival and proliferation of osteoclast progenitors
via upregulation of Bcl-xL while RANKL is responsible for
stimulating their differentiation.68
Described by its ability to inhibit osteoclast develop-
ment, the first molecule within the axis to be discovered
was OPG. OPG is a member of the tumor necrosis factor
receptor (TNFR) superfamily that is secreted due to a lack
of the transmembrane domain.69 As a soluble protein, OPG
binds and sequesters RANKL from binding RANK, thereby
inhibiting osteoclast activation. Transgenic mice that
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Figure 4 Members of the RANK signaling pathway. RANK is a member of the TNFR superfamily that is essential for osteoclas-
togenesis and function. After binding, TRAF adaptor proteins are recruited to the receptor complex to activate downstream
intracellular mediators. Like the other member of the TNFR family, RANK binds RANKL as a trimer to activate intracellular signaling
pathways. OPG, a decoy receptor, negatively regulates this pathway by binding and inactivating RANKL.
62 J.B. Maxhimer et al.overexpress OPG demonstrated both an increase in bone
density as well as osteopetrosis. Conversely, OPG knockout
mice exhibit profound osteoporosis.70e72 Not only did these
studies show a crucial role for OPG in the maintenance of
bone mass but they also suggested that OPG may neutralize
a TNF-related factor that could stimulate osteoclast
development.73 This factor was identified as RANKL or
originally called TRANCE (TNF-related activation-induced
cytokine).
RANK, a tumor necrosis factor superfamily receptor
originally identified in T lymphocytes and osteoblasts, is
now known to be essential for osteoclast differentiation
and activation upon binding to its cognate ligand.74,75
Knockout mice generated in these studies show that both
RANK and RANKL deficiencies resulted in osteopetrosis due
to a complete absence of osteoclasts.70,76 The binding of
RANKL with RANK results in the trimerization of the re-
ceptor and recruitment of the adaptor protein tumor ne-
crosis associated factor 6 (TRAF6) to the receptor complex.
Although the RANK complex can interact with other TRAFs,
only TRAF6 has been found to be essential for osteoclast
function.77,78 This interaction then activates a cascade of
intracellular signaling pathways including nuclear factor of
activated T cells 1 (NFATc1), mitogen activated protein ki-
nases (MAPKs) such as Jun N terminal kinase (JNK) and p38,
and NF-kB.66,77,79,80
The discovery of the RANK-RANKL-OPG axis has been a
critical breakthrough in the understanding of osteoclast
differentiation.81e84 While macrophage colony forming
units have been known to be a precursor to macrophages,
RANK activation induces differentiation into osteoclasts.
Most importantly, the characterization of RANKL allowed
the differentiation of osteoclasts in vitro and the ability to
perform mechanistic studies on osteoclasts. Due to thedirect relationship between the RANK-RANKL-OPG axis and
osteoclast activation, targeted therapies against the axis
are under investigation for fracture healing and other
conditions requiring a net osteogenic state.85Osteoclast activation in craniosynostosis
Beyond the physiological aspect that the RANK-RANKL-OPG
axis imparts on osteoclastogenesis, overactivity of the axis
is significant in the pathogenesis of certain diseases. In
terms of genetic descriptions, duplications in the signal
peptide of RANK have been linked to Paget’s disease, which
is characterized by focal areas of increased bone remod-
eling. Another disease called familial expansile osteolysis is
a rare autosomal dominant disorder that causes erosion of
long bones by progressive osteoclastic resorption. Further-
more, juvenile Paget’s disease is thought to be caused by
mutations affecting the ligand binding domain of OPG.86
These patients suffer from excessive osteoclastic bone
resorption and irregular bone formation that leads to bone
pain and deformities. Rheumatoid arthritis has also been
linked to osteoclast formation. More specifically, RANKL
expression in fibroblasts within the synovia has been shown
to lead to the formation of osteoclasts causing the bone loss
seen in the disease. In animal models, inhibition of RANKL
through OPG did not influence the severity of inflammation
but the treatment did stop the loss of bone in inflamed
joints of arthritic rats in a dose-dependent manner and
untreated animals saw a large increase in osteoclast
numbers.87
Unlike work on long bones and joints, alterations in os-
teoclasts are found less frequently in craniosynostosis. It is
likely that the reason this occurs is that a lack of osteoclast
Bone homeostasis mechanisms in craniosynostosis and bone tissue engineering 63function rather than excessive osteoclast activity results in
a severe systemic alteration which may not be compatible
with life. Nevertheless, heritable osteopetroses have been
reported in human diseases. Autosomal recessive osteo-
petrosis (ARO) is a rare, heterogeneous disease that pre-
sents soon after birth and frequently leads to postnatal
death.88,89 The incidence of ARO is 1:250,000, albeit the
incidence is higher in some geographical areas due to
consanguinity. The clinical manifestations of ARO are sec-
ondary to defective bone resorption, which has been re-
ported as a constellation of presentations including
craniosynostosis, macrocephaly, foraminal narrowing of the
skull base, structural brain malformations, frontal bossing,
exophthalmos, hypertelorbitism, and micrognathia. One of
the major problems facing patients with ARO is the
decreased immune response leading to a high risk for
osteomyelitis and other infections. The perturbations in
bony development of the calvarium have been documented
both radiographically and clinically. The characteristic
facies of ARO has been described to include frontal bossing,
exophthalmos, hypertelorbitism, midface hypoplasia, and
craniosynostosis. In fact, radiographic studies on the dis-
ease have demonstrated the characteristic harlequin sign
bilaterally signifying bicoronal craniosynostosis.90,91 ARO
can be divided into the subset of osteopetroses that are
osteoclast rich versus the subset that has a paucity of os-
teoclasts. In the majority of the ARO forms where the
defect is intrinsic to osteoclast function, the definitive
treatment is a bone marrow transplant for rescue. The
exception to the rule is when the defect affects RANKL, in
which a proof of principle investigation has suggested that
RANKL infusion may rescue the phenotype.92
The evidence that osteoclasts are important to suture
patency has been confirmed in an experimental ex vivo
murine model. Recent studies have demonstrated a novel
role for RANK-RANKL-OPG axis in cranial suture biology as
well as the development nonsyndromic craniosynostosis
through the fine balance of osteoblast and osteoclast
function. Using a well established model for cranial suture
biology, CD1 mice were examined for RANK expressions in
various cranial sutures. Immunohistochemical analysis
showed strong RANK staining at the junction of coronal and
sagittal sutures up to 12 weeks of age. Both of these sutures
are known to stay patent past 5 weeks of age. In contrast,
posterior frontal sutures which close in vivo around 5 weeks
of age showed decreased RANK staining. Similar results
were found when pathologically fused and patent sutures
were examined in human subjects. RANK expression in pa-
tients with known nonsyndromic craniosynostosis were
examined in the same manner as the murine model and
comparable results were found.93 Patent human coronal
sutures displayed high levels of RANK staining at the suture
junction in contrast to the low levels found within the
pathologically fused human sutures. Unlike the RANK re-
ceptor, the expression pattern for RANKL does not correlate
with suture patency. Both fused and patent sutures express
RANKL equally. Furthermore, levels of isolated RANK mRNA
were also examined at each time point in the respective
sutures as well as calvarial bone without suture. Interest-
ingly, levels of RANK mRNA decreased in a temporal fashion
regardless of the suture, suggesting that RANK expression is
not regulated at the transcription level but potentiallycontrolled at the posttranslational level. Lastly, RANK
knockdown in calvarial strip suture cultures demonstrated
an increase in bone density within patent sutures after
transduction with a small interfering RNA specific for
RANK.93
In summary, a model for bone homeostasis from the
pathways affected in craniosynostosis can be synthesized
(Fig. 5). Within the basic multicellular unit, osteogenic
signals are received by the osteoblast via FGF/FGFR and
BMP/BMPR pathways. Activation of both FGFR and BMPR
signaling pathways results in transactivation of osteogenic
genes. This transactivation is negative regulated by Twist1.
At the same time, activation of osteogenic genes simulta-
neously activates RANKL and OPG expression. RANKL binds
to RANK on the osteoclast to stimulate osteoclastogenesis
while OPG negatively regulates this process. The relative
quantity of RANKL to OPG is likely to be an important factor
in osteoclast activity. Within mineralized bone, osteocytes
also secrete RANKL and OPG via its canalicular network.
Although not discussed in this review, osteocytes are also
the main sources for sclerostin, which is an important
regulator of the Wnt pathway.From suture biology to skeletal tissue
engineering
The strides in molecular genetics and signaling achieved
through the understanding of cranial suture biology and
congenital craniosynostoses have been extensive in the
past 25 years. Despite all of these advances, craniosynos-
tosis remains a surgical disease. Especially in syndromic
cases, the abilities to decompress elevated intracranial
pressure or protect the exophthalmic globe from exposure
are not yet in the realm of pharmacologic or genetic ther-
apies. However, these basic studies have been instrumental
in effecting advances in skeletal regenerative technologies
which have the potential of clinical relevance beyond rare
congenital conditions.
The conceptual approach to bone tissue engineering is to
direct regeneration by applying osteogenic factors to a
specific three-dimensional space. Current methods used to
accomplish this concept usually include three elements:
osteogenic cells, scaffolding material, and growth fac-
tors.94,95 Strategic placement of the proper combination of
cells and growth factors can support both recruitment of
osteogenic cells from the host environment and osteo-
genesis on the scaffold. Scaffolding material, traditionally
thought to be an inert structure, is now known to have
differential abilities to support osteogenesis depending on
the material, porosity, and ability to mimic the normal
extracellular matrix.94 Contemporary bone tissue engi-
neering research aims to optimize the delivery of the three
components to generate a stable quantity of bone that fully
integrates into the human body and sustains the test of
time.
Advances in bone tissue engineering have historically
generated great excitement initially; however, most at-
tempts at transfer have largely failed. In 2001, Vacanti
and colleagues excited the field of tissue engineering
with the implantation of an engineered distal phalanx
containing periosteum-derived cells on a phalanx shaped
Figure 5 Lessons on bone homeostasis from cranial suture biology. From the many genetic and mechanistic studies on the
craniosynostosis and cranial suture biology, contributions on interplay between the basic multicellular unit for bone homeostasis
have been elucidated. From the bone formation perspective, the FGFR gain of function mutations and Twist1 loss of function
mutations result in dysregulated bone formation. Twist 1 downregulates not only the FGFR signaling but also BMPR signaling. From
the osteoclastogenic perspective, RANK axis mutations have severe phenotypes in human disease and are frequently incompatible
with life. In the rare surviving patients, RANK or RANKL loss of function inhibits osteoclast function causing craniosynostosis and
osteopetrosis. However, these opposing processes are significantly intertwined. Osteogenic gene activation also increases secretion
of RANKL and OPG from osteoprogenitors. Similarly, the osteocyte is also a source of RANKL and OPG.
64 J.B. Maxhimer et al.hydroxyapatite scaffold.96 Similarly, Warnke and colleagues
reported implantation of an engineered, autologous human
mandible using hydroxyapatite blocks and a titanium mesh
scaffold.97,98 However, the course for this patient was
marked with fracture of the mesh/bone junction, infection,
and necrotic bone. In this work, engineered bone bores
minimal advantages, at best, and some disadvantages in
comparison to the bone graft substitutes that currently
exist. Furthermore, both groups and other in-
vestigators99,100 have shown data using a hydroxyapatite
scaffold, known to be osteoconductive, even in the absence
of osteogenic cells. Thus, without a formal direct compar-
ison with hydroxyapatite scaffolds alone, the advantages of
these processes are difficult to measure. Smaller bone de-
fects have fared better.101e103 Hibi and colleagues103 have
reported a process using autologous serum and bone
marrow to generate osteogenic material that was able to
induce and/or conduct osteogenesis in alveolar clefts.
Schimming and Schmelzeisen demonstrated success in
approximately 66% of their patients using autologous peri-
osteal osteoprogenitors for maxillary sinus augmenta-
tion.101,102 Both groups demonstrated that in small bone
defects, bone engineering has the potential to be accom-
plished but carries its own morbidity as well as some dis-
advantages in comparison to surgical bone grafting or bonegraft substitutes. In small defects such as alveolar clefts, it
is also important to acknowledge that recombinant BMP-2
alone is also capable of healing via osteoinduction.104,105
Unfortunately, long term follow up of BMP-2 treatment in
alveolar clefts showed untoward effects on maxillary
growth.106 This highlights the need for therapies that do not
rely primarily on exogenous, supraphysiological quantities
of growth factors. Like the study of craniosynostosis, the
primary focus of bone tissue engineering has been on
making bone with minimal to no consideration for bone
breakdown.
From the knowledge gained from studying craniosynos-
tosis, a number of molecules have been utilized to increase
in vitro osteogenesis and in vivo models of bone healing.
Within the FGF pathway, a multitude of scaffolds have been
combined with FGF-2 for bone regeneration.107 FGF-2 in
combination with BMP-2 have shown the ability to increase
osteogenesis of bone marrow derived mesenchymal stem
cells in a temporal fashion.108 In calvarial defects, chemical
tunable FGF-2 can induce in vivo bone healing in adipose-
derived stem cells.109 Twist1 knockdown in human adipose-
derived stem cells have demonstrated an increase in BMP
and FGF signaling resulting in osteogenic differentiation.110
Certainly, the BMP pathway has received the most atten-
tion in both the laboratory and the clinical realm for making
Bone homeostasis mechanisms in craniosynostosis and bone tissue engineering 65bone. Two obstacles that have plagued bone engineering
are the presence of inflammation after implantation of
bone and long term resorption. In studies with human
mesenchymal stem cells, this is frequently overlooked in
laboratory investigations in that the human cells and scaf-
folds are implanted into immunocompromised recipients.
However, inflammation is more apparent when non-human,
immunocompetent models are utilized. Although the
reason for inflammation in syngeneic, immunocompetent
models may be multifactorial, it is likely that the scaf-
folding material may be part of the reason. A multitude of
scaffolds have been reported in the literature comprised of
biodegradable polymers, extracellular matrix components,
or combinations thereof. Polymers made of poly-L-lactic
acid and poly-L-glycolic acid have been long tested in our
laboratory and others as a scaffold material for bone en-
gineering. Both substances and their derivatives have been
in use as resorbable suture material and resorbable plates
and screws for skeletal defects. Both substances degrade
into acidic metabolites, thereby inducing inflammation via
superoxide release from phagocytes.111,112 In small defects,
local inflammation may be relatively inconsequential for
bone resorption. However, when the defect is large enough
to warrant replacement, prolonged inflammation may
resorb the quantity of bone necessary for engraftment. This
realization has led many investigators to find ways on
decreasing inflammation in an effort to decrease resorp-
tion. Interestingly, the initiation of osteogenic differentia-
tion is also related to resorption in that RANKL and OPG
expression increase. The amount of increase is temporally
dependent and the ratio of RANKL to OPG also varies in a
temporal manner (JCL, unpublished observations). Because
osteogenesis induces the expression of RANK and OPG in
mesenchymal stem cells, additional attention to the RANK
axis and osteoclastogenic activation may be an important
consideration to the future of tissue engineering.Conclusions
The lessons learned from cranial suture biology have
impacted both an understanding of the pathogenesis of
congenital craniosynostosis as well as opened new avenues
of investigation in bone tissue engineering. Like all biology,
the pathways are complex, the players are varied in cell
types, and perturbations of homeostasis can result in
different outcomes. The future of reconstructive surgery is
regenerative surgery and these lessons are invaluable ad-
vances towards clinical solutions.Conflicts of interest
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